Main contents of the two sessions of the National People's Congress in 2121

(1) Agenda of the Fourth Session of the 13th National People's Congress

1. Review the government work report

2. Review the 14th Five-Year Plan for National Economic and Social Development and the draft outline of the long-term goals in 2135

3? Review the implementation of the plan for national economic and social development in 2121, the report on the draft plan for national economic and social development in 2121 and the draft plan for national economic and social development in 2121

4? Review the implementation of the central and local budgets in 2121, the report on the draft central and local budgets in 2121, and the draft central and local budgets in 2121

5? Deliberating the proposal of the NPC Standing Committee to submit for deliberation the Organic Law of the People's Republic of China and the National People's Congress (Revised Draft)

6? Deliberating the proposal of the NPC Standing Committee to submit for deliberation the Rules of Procedure of the National People's Congress of the People's Republic of China (Revised Draft)

7? Review the NPC Standing Committee's work report

8? Review the Supreme People's Court's work report

9? Deliberating the work report of the Supreme People's Procuratorate

(II) Agenda of the Fourth Session of the 13th Chinese People's Political Consultative Conference

1. Hearing and deliberating the work report of the Standing Committee of the National Committee of the Chinese People's Political Consultative Conference

2. Hearing and deliberating the report of the Standing Committee of the National Committee of the Chinese People's Political Consultative Conference on the proposal work

3. Attending the fourth session of the 13th National People's Congress, Hearing and discussing the government work report and other relevant reports

4. Examining and passing the political resolution of the Fourth Session of the 13th National Committee of the Chinese People's Political Consultative Conference

5. Examining and passing the resolution of the Fourth Session of the 13th National Committee of the Chinese People's Political Consultative Conference on the work report of the Standing Committee

Note: The schedule changes shall be subject to the official notice.

fourth, what impact does the NPC and CPPCC have on the stock market?

when the market enters the two sessions. Hot issues such as policy tone, epidemic prevention and control, economic data, development goals and people's livelihood have become the focus of global attention. At the same time, the stock market also officially entered the two sessions. Next, let's analyze the stock market of the two sessions over the years and the impact of the two sessions on the broader market this year.

from the historical data, the stock market shows a certain? Two sessions effect? . Securities Times? According to statistics, in the past ten years (2111-2119), the Shanghai Composite Index rose six times during the two sessions, and all the Shanghai Composite Index achieved positive returns during the two sessions in the past five years. After the end of the two sessions, the upward trend of the market continued in the short term, and the benefits formed by the introduction of relevant policies continued to ferment after the meeting. Five days and 11 days after the end of the two sessions, the rising probability of the market reached 61% and 71% respectively, and the increase was expanding.

Growth Enterprise Market performed even better during the two sessions, with a winning rate of two-thirds. During the two sessions in recent ten years, the growth enterprise market index rose by 1.51% on average, which was better than the performance of the Shanghai Composite Index in the same period. During the two sessions in 2119 and 2118, the growth rate of GEM index was as high as 6.14% and 5.23% respectively. On the whole, the positive signals released by the two sessions played a positive catalytic role in the stock market trend.

the winning rate of food and beverage industry during the two sessions was 81%

during the two sessions, the trends of various industries were divided, and most industries performed relatively flatly. According to the statistics of Data Treasure, in the past decade, only the food, beverage and communication industries among the 28 first-class industries won more than 51% during the two sessions, reaching 81% and 61% respectively, and the food and beverage industry was the absolute winner. The winning rate of five industries, such as mining, nonferrous metals and transportation, is only 31%.

in terms of the index fluctuation, only 11 industry indexes increased by more than 1 on average during the two sessions in the past ten years, among which, the pharmaceutical biological index increased the highest on average, reaching 1.41%, and the food and beverage industry increased by 1.34% on average, ranking second. Steel, mining, national defense and military industry, and non-bank finance performed the worst, with an average decline of more than 1.3%.

CMB International predicts that the government will continue to support domestic demand and consumption extensively, while promoting infrastructure investment and employment in a targeted manner. Statistics over the years show that most consumer stocks outperformed the market before and after the two sessions. Considering this year's policy support and external risks, this year's consumer stocks (including retail, catering, automobile, education, e-commerce, etc.) are expected to continue to benefit from the two sessions and become winners.

In addition, infrastructure investment will remain an important support for economic growth, and it is expected that the government will approve more infrastructure projects after the two sessions. CMB International expects that the demand for construction machinery and heavy trucks will continue to rise in the second half of this year. Related targets include Sany Heavy Industry, Hengli Hydraulic, Weichai Power and Zhejiang Dingli.

under the influence of the COVID-19 epidemic, the pharmaceutical sector is also the most concerned focus. Huaxi Securities believes that there are three main investment lines worthy of attention in the medical theme:

First, the construction of medical facilities: the epidemic situation will promote the replenishment of medical facilities, and the purchase of medical equipment under the new infrastructure in the future will promote the construction of medical facilities. After the epidemic, the demand for some specific medical equipment will definitely increase greatly. The list of medical equipment urgently needed for epidemic prevention and control in COVID-19 issued by China Medical Equipment Association involves 18 listed companies, including Wanfu Bio, Mindray Medical, Edan Instrument, Wandong Medical and Yuyue Medical.

second, vaccines: the epidemic situation in COVID-19 has improved the awareness rate of vaccines, and the long-term vaccination rate of vaccines will continue to increase. From the investment points of the vaccine industry and the future market space of heavy varieties, the product pipeline is becoming more and more important to the company, especially the heavy non-immunization planned vaccine with significant improvement and exclusive advantages.

The targets of A-share listed companies in related segments include: Zhifei Bio (Mycobacterium vaccae vaccine, AC-Hib triple vaccine, diploid wild vaccine, 15-valent pneumonia conjugate vaccine, tetravalent norovirus vaccine, etc.), Kangtai Bio (13-valent pneumonia conjugate vaccine, diploid wild vaccine, quadruple vaccine &; Pentavalent vaccine, pentavalent rotavirus vaccine, etc.), Hualan Bio (tetravalent influenza vaccine, rabies vaccine, AC conjugate vaccine, etc.), Changchun Gaoxin (nasal spray influenza vaccine, rabies vaccine, herpes zoster vaccine, varicella vaccine, etc.), watson biological (trivalent pneumonia conjugate vaccine, bivalent HPV vaccine, etc.), etc.

thirdly, innovative drugs: the importance of research and development of innovative drugs is more obvious under the epidemic situation. Innovative drugs and biopharmaceuticals: Hengrui Pharma, China biopharmaceuticals, Hansen Pharmaceutical, Unacon, Beida Pharmaceutical, Haisike, Kelun Pharmaceutical, Fosun Pharmaceutical, Kanghong Pharmaceutical, tonghua dongbao; CXO (Pharmaceutical Outsourcing) field targets: Wuxi PharmaTech, Boteng, Tiger Medicine, Zhaoyan New Drugs, etc.